FDA likely to approve new recombinant hemophilia drug

Print Friendly, PDF & Email

A recombinant fusion drug combining the Factor VIII protein with an FC antibody peptide to extend its lifetime in circulation has been approved for treating hemophilia A, the FDA said Friday.

Called Eloctate, the drug is made by Biogen Idec of Cambridge, Mass. The FDA said it was the first product of its kind to win its approval for the condition. Currently, hemophilia A is treated with recombinant Factor VIII or concentrates derived from blood donations.

Specific indications include control and prevention of bleeding episodes, management of bleeding during surgical procedures, and prophylaxis against bleeding episodes.

Read the full, original story: Hemophilia A Drug Gets FDA Nod

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
a bee covered in pollen x

Are GMOs and pesticides threatening bees?

First introduced in 1995, neonicotinoids ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists